Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 15/20 | 0.64 |
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147533 | 0.95 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1HPGDRAB9ANPC1 | |
| SCHEMBL10147523 | 0.92 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1 | |
| SCHEMBL10180486 | 0.91 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1 | |
| SCHEMBL10182285 | 0.91 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1 | |
| SCHEMBL10147525 | 0.90 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1 | |
| SCHEMBL10147528 | 0.90 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1 | |
| SCHEMBL10147531 | 0.89 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1 | |
| SCHEMBL10147544 | 0.88 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1 | |
| SCHEMBL10147568 | 0.87 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1 | |
| SCHEMBL659551 | 0.85 | HSP90AA1 (0.82) | HSP90AA1HSP90AB1HPGDRAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885HPGD 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.